Method for preparing bismuth iodide sulfamide

FIELD: veterinary science.

SUBSTANCE: invention relates to methods for preparing chemotherapeutic preparation comprising biologically active iodine. Method for preparing bismuth iodide sulfamide is carried out by addition of bismuth basic nitrate to potassium iodide an aqueous solution and heating the reaction mass in acid medium up to 75-80oC. Then streptocide is added and heating is continued up to 100-105oC, kept at this temperature up to the melt formation followed by cooling and grinding. Method provides preparing the end product with the content of elemental iodine 10.8-11.0% by the wasteless technology for a single stage.

EFFECT: improved preparing method.

3 ex

 

The invention relates to veterinary medicine, and in particular to methods of obtaining chemotherapy drugs, containing biologically active iodine.

A known method of producing godisgoodalltime by A.S. 263809, 1969, "the Method of producing drug for treating latent endometritis in animals" (authors Nihalani, WinPopup, Metropolol).

The known method involves several sequential steps for implementing each of them requires appropriate equipment and means of protection. First prepare the nitrate guidesthe bismuth interaction of bismuth nitrate basic with itestosterone acid. The resulting product of pasty consistency incubated for 12 h in a fume hood, and then dried under thrust. Brought to air-dry state nitrate guidesthe bismuth grind him to powder. In the next phase of streptocide prepare hot saturated aqueous solution; in the latter portion of the injected nitrate guidesthe bismuth in an amount of 10% relative to the streptocide. The mixture is left for a day for the deposition of the reaction products. The precipitate was separated from the supernatant liquid by filtration through a Buchner funnel, washed with distilled water, squeezed and dried in a specially equipped room. After drying, grind to powder, then sift.

The target product of sod is RIT 3.5% iodine and 4.0% of bismuth. From it is prepared dosage forms for intrauterine application: emulsion vismutsurma (Veterinary medicines. Directory edited Addmetadata. M, Agropromizdat, 1985, s-174) and sticks metromax (Rational use of drugs in veterinary medicine. M, Rosselchozizdat, 1984, pagination 126-129).

Thus, the manufacture of godisgoodalltime (powder) is a cumbersome procedure, but some of the original components and reaction products is lost to leaching waters and the supernatant fluid. About 75% by weight of the target product presents residual sulfonamides, which is not justified as in the clinical aspect, and in economic terms.

The purpose of the invention is the obtaining of godisgoodalltime (powder) for wasteless technologies, in a single phase, with a higher content of biologically active iodine, with the exception of the loss of initial components and getting them into the environment.

This goal is achieved by the fact that in the method of producing godisgoodalltime based on the interaction of streptocide with nitrate guidesthe bismuth, the latter is obtained by introducing basic bismuth in an aqueous solution of potassium iodide and catalysis of chemical reactions by creating an acidic environment and heating the reaction mass up to 75-80°C. On reaching the set temperature is URS enter streptocid and continue the slow heating up to 100-105° C. This leads to the gradual dehydration of the target product and its transition in the melt state; this condition prevents recrystallization.

To obtain 1 kg of the proposed drug in stainless steel tanks with temperature control bottom measure 250 ml of distilled water, it is dissolved in 230 g of potassium iodide. In the solution contribute 200 g of bismuth nitrate basic, poured 16 ml of hydrochloric acid of specific gravity 1,19. Capacity put on a slow heat, which is conducted with vigorous stirring with a wooden spatula. In the course of the reaction the formed nitrate guidesthe bismuth in the form of an amorphous mass of brown color.

After the temperature of the reaction medium reaches 75-80°without mixing, fall asleep 570 g streptocide (poorly) and continue heating to T 100-105°C. the Product of the reaction is maintained at this temperature for 8-10 minutes, the result is its dehydration with subsequent transition in the molten state. The capacity to melt remove from heat, allow to cool to room temperature. Hardened mass in the form of small pellets ground to powder.

The finished product - godisgoodalltime M is an amorphous powder, intense brick-red, odorless, slightly soluble in water.

Obtained by the claimed method, according to the calculations, the content is it 10,8-11,0% elemental iodine, i.e. three times more in comparison with the known. This accordingly allows to reduce the dose while maintaining high pharmacological activity.

In examples 1 and 2 shows comparable data on the content of godisgoodalltime in medicinal forms for intrauterine application made and claimed by known methods.

Example 1 (emulsion godisgoodalltime).

The inventive methodThe known method
Godisgoodalltime, wt.%3,510,0
Drug basis, wt.%96,590,0

Example 2 (metromix).

The inventive methodThe known method
Godisgoodalltime, wt.%13,032,0
Drug basis, wt.%of 87.068,0

Example 3. Studied physical stability of godisgoodalltime made by the claimed method, and its dosage forms. Control samples of godisgoodalltime powder, a 3.5%emulsion and sticks metromax stored for 10 months at room temperature in the light and in the dark place. The hedgehog is conducted monthly visual evaluation. For a controlled period of time was not observed color changes and patterns of powder godisgoodalltime and sticks metromax.

Emulsion dosage form of the drug retains the original color and uniformity; the precipitated solids were missing.

From these examples it follows that godisgoodalltime made by the claimed method, more economical, has a high physical stability of both the powder and the composition of the dosage forms intended for intrauterine use.

The method of producing godisgoodalltime, including mixed salts of bismuth with streptocide, characterized in that salts of bismuth using bismuth nitrate basic, which is made with hydrochloric acid in an aqueous solution of potassium iodide and lead a slow heating up to T° 75-80°With, then add streptocid and continue heating to T° 100-105°C, kept at this temperature for 8-10 min before the formation of the melt is then cooled and pulverized.



 

Same patents:

Antibacterial gel // 2247555

FIELD: cosmetology.

SUBSTANCE: the present innovation deals with cosmetic preparation for taking care of skin, in particular. The suggested antibacterial gel consists of either hydroxypropylcellulose or hydroxyethylcellulose, propylene glycol or diethylene glycol compound, polyguanidine or its synergistic mixture with quaternary ammonium compound, chitosan, oxyethylated ether of sorbitane, polyvinyl pyrrolidone at molecular weight ranged 10000 - 40000 or copolymer of polyvinylpyrrolidone, trilon-B - sodium salt of ethylene diamintetraacetic acid, perfumery composition, vitamin constituent and water. The present innovation provides increased regenerating formula of skin and its enhanced barrier function, improves homogeneity of the composition mentioned and its stability.

EFFECT: higher efficiency of application.

5 cl, 4 ex, 3 tbl

FIELD: organic chemistry, antibacterial agents.

SUBSTANCE: invention describes 8-cyano-1-cyclopropyl-7-(1S,6S)-2,8-diazabicyclo-[4.3.0]-nonane-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinoline carboxylic acid of the formula (I): with the crystalline modification A and a drug eliciting effect against pathogenic microorganisms. The prepared crystalline modification shows stability and doesn't transform to another crystalline modification or amorphous form being even at prolonged storage.

EFFECT: improved and valuable properties of compound.

4 cl, 4 dwg, 6 ex

FIELD: organic chemistry, medicine.

SUBSTANCE: invention relates to applying compounds of the formula (I) for preparing an antibacterial composition and veterinary composition eliciting with the enhanced activity.

EFFECT: valuable properties of agents.

4 cl, 3 tbl, 78 ex

FIELD: medicine, pharmaceutical industry, pharmacy.

SUBSTANCE: invention relates to compositions used for treatment and/or prophylaxis of chlamydium infections caused by C. pheumoniae. Pharmaceutical composition used for treatment and/or prophylaxis of chlamydium infection caused by C. pneumoniae comprises the taken phenolic compound, or extract, or fraction, or incomplete fraction comprising the taken phenolic compound or corresponding synthetic compound, or mixture of indicated compounds obtained from plants. An anti-chlamydium effect of phenolic compound or extract, or fraction, or incomplete fraction obtained from plants and comprising indicated compound or corresponding synthetic compound on C. pneumoniae represents the definite percent of inhibition for formation of inclusions. The composition useful for health eliciting an anti-chlamydium effect with respect to C. pneumoniae comprises the taken phenolic compound or extract, or fraction, or incomplete fraction containing indicated compound or corresponding synthetic compound, or mixture of indicated compounds obtained from plants. An anti-chlamydium effect of phenolic compound or extract, or fraction, or incomplete fraction comprising indicated compound or corresponding synthetic compound obtained from plants on C. pneumoniae represents the definite percent for inhibition in formation of inclusions. Also, invention relates to applying the composition useful for health in preparing foodstuffs or as supplements for nutrition for every day. Also, invention relates to applying phenolic compound or extract, or fraction, or incomplete fraction comprising indicated compound or corresponding synthetic compound or mixture of indicated compounds obtained from plants in manufacturing a medicinal agent used for treatment and/or prophylaxis of chlamydium infections caused by C. pneumoniae. An anti-chlamydium effect of phenolic compound or extract, or fraction, or incomplete fraction comprising indicated compound or corresponding synthetic compound obtained from plants on C. pneumoniae represents the definite percent in inhibition in formation of inclusions. Compositions promote to effective prophylaxis and treatment of chlamydium infections caused by C. pneumoniae.

EFFECT: valuable medicinal properties of compounds.

21 cl, 1 dwg, 1 tbl, 6 ex

FIELD: biotechnology, vaccines.

SUBSTANCE: vaccine comprises bacterial mass of Pasteurella multocida of serovariants A, B and D, Haemophilus pleuropneumonia of serogroups 1 and 2, and streptococcus of serogroups C and R, and also lysate-anigens of salmonellae Salmonella cholerae - suis, strain № 370 and Salmonella typhimurium № 415 mixed in the definite concentration. Vaccine elicits the high immunogenicity and provides the protection of pigs against infectious pneumonia of bacterial etiology and salmonellosis.

EFFECT: valuable veterinary properties of vaccine.

3 cl, 1 tbl, 5 ex

FIELD: veterinary science.

SUBSTANCE: the method deals with injecting oxylate once daily for 3 d at the dosage of 1 ml/30 kg body weight at repeated therapy course in 5 d at the background of antibioticotherapy. The method enables to normalize biochemical and morphological blood values and increase average daily body weight gain in sick animals.

EFFECT: higher efficiency of therapy.

2 ex, 2 tbl

FIELD: organic synthesis.

SUBSTANCE: invention provides substituted 7-acylaminocephalosporins of formula I:

(I), where W denotes CH or B; V denotes NO; R1 hydrogen or С14-alkyl; R3 hydrogen or ester residue; and R2 one of the following groups: , , , , in which X, R5, R6, R'6, R7, and Hal have meanings indicated in claims, in free state, in the form of salts and/or solvates, or, if such forms are stable, in the form of internal salt, quaternary salt, or their hydrates, possessing antimicrobial activity. Invention also discloses a method for preparing such compounds and a pharmaceutical connected containing them.

EFFECT: increased choice of antimicrobial preparations.

13 cl, 10 tbl, 225 ex

FIELD: pharmaceutics.

SUBSTANCE: composition is constituted by effective amount of thymol obtained from plant Trychyspermum ammi, mint oil combination of mint oil containing required amounts of monoterpenes and isolated from Mentha spicata and Mentha arvensis, and typical additives. Invention also relates to preparation of the composition by mixing above ingredients and to method of treating patients by administering therapeutically effective amount of the composition.

EFFECT: created therapeutic agent overcoming drug resistance of bacteria and minimized or even eliminated secondary adverse effect of drug.

19 cl, 12 tbl, 11 ex

FIELD: pharmacology, fluorinated quinolone-based drug, in particular ofloxacine for injections.

SUBSTANCE: claimed composition contains therapeutically acceptable amount of ofloxacine and trilon-B, sodium chloride, water for injections as additives.

EFFECT: high therapeutic effectiveness; non-crystallized active agent for a long-time storage.

1 ex

FIELD: biotechnology, medicine, infectious diseases, medicinal microbiology.

SUBSTANCE: invention relates to a composition designated for treatment and prophylaxis of infections caused by Neisseria microorganism that comprises the following components: (a) protein with amino acid sequence similar by 65% and above with the natural Neisseria protein of a single species (the first group of amino acid sequences is given in the text) and/or its fragment consisting of 10 and more amino acids and eliciting antigen properties; (b) the second protein with amino acid sequence similar by 65% and above with the natural Neisseria protein of another species (the second group of amino acid sequences with even numbers is given in the text), and/or its fragment consisting of 10 or more amino acids and eliciting antigen properties; in particular, the second protein represents NspA. The composition comprises additionally adjuvant. The composition is used both a medicinal agent and for manufacturing the medicinal agent. Applying the invention provides enhancing the effectiveness of prophylaxis or treatment due to the universal effect of the composition (vaccine). Invention can be used in medicine for treatment of infections.

EFFECT: valuable medicinal properties of composition.

8 cl, 137 dwg, 5 tbl, 12 ex

FIELD: medicine; medical engineering.

SUBSTANCE: means is composed of spherical and close-to-spherical 500-3000 mcm large microgranules. Microgranule matrix has at least one cross-linked polymer and fillers. The cross-linked polymer is taken as sodium alginate, or gelatin, or pectin, or carraginan, or agar-agar, or sodium salt of carboxycellulose, or copolymer of acrylic acid and butylacrylate, or their mixtures. The fillers are hyperosmolar, antiseptic, anesthetic and, when required, antioxidant compounds. Method involves placing microgranules into pyoinflammatory lesion focus through postoperative or fresh wound. Wound cavity space is filled with microgranules to not more than one-half of its volume. Then the wound is drained and covered with antiseptic bandage. The granules and bandage are changed once a day during 2-3 days.

EFFECT: enhanced effectiveness of treatment; prolonged drug concentration support in wound.

6 cl,1 tbl

The invention relates to medicine and can be used for the treatment of angina

The invention relates to medicine and can be used in surgery, dentistry, gynecology, traumatology, sports medicine, at home, with operating procedures and the damage associated with bleeding, especially in the presence of infection
The invention relates to medicine, in particular to the gynecologist, and for the treatment of chronic adnexitis

The invention relates to medicine, specifically to the means which have an antimicrobial effect on local purulent-inflammatory processes of the soft tissues and used in surgery, dermatology, obstetrics, gynecology, otolaryngology
The invention relates to General surgery, traumatology and military surgery and can be used for preoperative treatment of the skin and the processing of the wound surfaces operating and traumatic wounds
The invention relates to pharmaceutical industry

The invention relates to medicine, in particular to purulent surgery in the treatment of abscesses and phlegmon, as well as burn wounds

The invention relates to medicine and applies glue antiseptic wound healing, which includes Miramistin, ethyl alcohol and glue BF-6 in a ratio

Disinfecting agent // 2246953

FIELD: sanitary and hygienic materials.

SUBSTANCE: water-based disinfecting composition contains water-soluble cyclodextrin-iodine inclusion complex and/or derivatives thereof, iodine, iodide ion source, organic solvent, and, if necessary, surfactant and/or functional additive, all in specified proportions. Agent possesses wide spectrum of antimicrobial effects at low concentrations. It does not irritates skin, shows no toxicity, and is stable upon storage within a wide temperature range.

EFFECT: increased choice of high-efficiency disinfecting agents.

19 cl, 2 tbl

Up!